Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) to a hold rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Oramed Pharmaceuticals in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Oramed Pharmaceuticals Price Performance

Shares of ORMP opened at $2.39 on Friday. The firm has a market cap of $98.00 million, a P/E ratio of -6.83 and a beta of 1.62. The stock has a 50 day simple moving average of $2.35 and a two-hundred day simple moving average of $2.24. Oramed Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $3.09.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its earnings results on Thursday, August 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, equities analysts anticipate that Oramed Pharmaceuticals will post -0.03 earnings per share for the current year.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ORMP. Peapod Lane Capital LLC raised its holdings in shares of Oramed Pharmaceuticals by 11.0% during the first quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company’s stock valued at $540,000 after acquiring an additional 24,985 shares in the last quarter. BML Capital Management LLC raised its holdings in shares of Oramed Pharmaceuticals by 14.3% during the first quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company’s stock valued at $6,464,000 after acquiring an additional 376,841 shares in the last quarter. N.E.W. Advisory Services LLC raised its holdings in shares of Oramed Pharmaceuticals by 52.9% during the first quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 6,540 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Oramed Pharmaceuticals by 35.3% during the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock valued at $144,000 after acquiring an additional 17,510 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Oramed Pharmaceuticals by 36.2% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 5,000 shares in the last quarter. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.